E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with progressive keratoconus disease |
|
E.1.1.1 | Medical condition in easily understood language |
Keratoconus affects the young, presenting in adolescence with impaired vision. This distortion of vision is due to the forward bowing of the weakened cornea. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10023353 |
E.1.2 | Term | Keratoconus |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the clinical trial is to establish whether cross-linking is efficacious in stabilising the progression of keratoconus, and whether it is safe in patients under 17 years. The main outcome measure will be the change in Kmax overall in the 2 groups in the time from randomisation and completion of 18 months follow-up. Kmax is an indicator derived from corneal topography and changes in this measure indicate whether keratoconus is progressing or not. Safety of CXL will also be monitored carefully at all follow up time points. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to measure the effect of CXL on keratoconus progression from baseline to 18 months in both arms of the trial, including the requirement for change from spectacle to rigid contact lens correction of vision. We will measure keratoconus progression (defined as more than 1.5 dioptres Kmax increase from randomisation) in individual patients, visual acuity with and without glasses or contact lenses, refraction (the measurement for glasses or contact lenses), central corneal thickness, patient-reported visual function and quality of life. Secondary safety outcomes in CXL-treated corneas include corneal opacification, infection and endothelial cell density.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Children and young patients aged 10-16 years with keratoconus progression confirmed in one or both eyes by Pentacam corneal topography. Progression will be defined as an increase of at least 1.5D in Kmax on corneal topography between two Pentacam examinations at least three months apart. - Patients must be sufficiently fluent in English to provide informed consent and completion of the patient reported outcome measures. - Patients must be willing to attend for follow-up visits. |
|
E.4 | Principal exclusion criteria |
- Advanced keratoconus as determined by apex corneal scarring. - Apex corneal thickness <400μ. - Maximum corneal curvature (Kmax) >60 diopres. - Rigid contact lens wear in both eyes and unable to abstain for 7days pre-examinations. - Corneal co-morbidity. - Down's syndrome. - Any clinical condition which the investigator considers would make the patient unsuitable for the trial, including pregnancy. - Participation in other clinical trials which would materially impact on the Keralink study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary outcome measure is Kmax in the study eye at 18 months post randomisation NB. The study eye is defined as the eye with the more advanced keratoconus at randomisation. The same intervention will be offered for the second eye for patients with progression in both eyes, unless the patient does not wish to receive the same intervention. Information from the second treated eye will be included in secondary analysis.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The timepoint for evaluation will be the 18 month follow-up visit post randomisation, however, for participants with progression at the 18 month visit a second timepoint at 21 month will be used to confirm this progression. |
|
E.5.2 | Secondary end point(s) |
a) Keratoconus progression (yes/no) defined as >1.5 dioptre increase in Kmax* from baseline (at randomisation) to 18 months or requirement for change from spectacle to rigid contact lenses correction of vision, as the latter precludes reliable topography measures b) Time to Keratoconus progression c) Uncorrected and best corrected visual acuity (measured as logMAR) d) Refraction (measured dioptres spherical equivalent, myopia and astigmatism) e) Central corneal thickness (ultrasound) f) Quality of life as assessed by CHU9D and VF-14 questionnaires
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The timepoint for evaluation will be the 18 month follow-up visit post randomisation, however, for participants with progression at the 18 month visit a second timepoint at 21 month will be used to confirm this progression. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
standard treatment with glasses and / or contact lenses |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 31 |